Message from the CHair
|
Dear Conference Attendees,
Welcome to the 27th Annual American Association of Pharmaceutical Scientists Northeast Regional Discussion Group (AAPS-NERDG) Meeting. We are once again hosting our conference in Groton-Mystic area. Bringing our conference back to April, it will be a great opportunity to enjoy some spring time ocean breeze. This year we have a lineup of impressive speakers from industry and academia alike. We will start the day with the morning keynote which will be delivered by Dr. Patrick Sinko, Distinguished Professor of Pharmaceutics at Rutgers University. Dr. Sinko’s research focuses on biopharmaceutics, |
|
pharmaceutical formulations, and molecular-, nano-, and micro-scale drug delivery with specific applications to the treatment or prevention of HIV/AIDS, cancer, chemical terrorism countermeasures, and tuberculosis. He will be sharing with us on Chemical Threats Countermeasures: From Repurposing to Innovative Delivery. The afternoon keynote will be presented by Dr. Sudhakar Garad, Global Head of Chemical and Pharmaceutical Profiling and Technical R&D, Biopharmaceutics Head at Novartis Biomedical Research, where his main role is to enable research, clinical, and commercial molecules via novel delivery technologies. Throughout the 23 years of his career, Dr. Garad has worked on more than 300 new chemical entities in clinical studies across multiple disease areas and many routes of administrations. Dr. Garad will discuss about Evolution of Drug Products and Drug Therapies in the Pharmaceutical Industry via his broad career journey experiences.
After the Morning Keynote, six students will present on their research to compete for the Academic Research Award (ARA). Concurrently, there will be three sessions of Short Topic Presentations (STP) with talks on a range of pharmaceutical research areas. We will once again have awards for the best STP presenters from each category. Winners from both sessions will be announced in the Awards Ceremony later in the day.
Before and after lunch, there are two exciting scientific presentations by DigiM and Simulations Plus, followed by one hour of Poster Session. All attendees will have an opportunity to interact with poster presenters and have great scientific discussions. Four Round Table Discussion sessions will follow, which include in-depth presentations by our panelists on emerging topics in pharmaceutical development. After our Second Keynote, our conference will conclude with an Awards Ceremony followed by a Networking Reception.
A vendor exhibition is available throughout the day, please take some time to visit their exhibition tables and listen to their technical talks. This conference would not be possible without our sponsors, supporters, and the incredible group of volunteers who have tirelessly worked to organize this year’s conference. Putting together an event of national recognition requires a lot of commitment, planning, and flexibility – it truly takes a village. This meeting wouldn’t be possible without their hard work and dedication to AAPS-NERDG.
Please enjoy the conference!
Sincerely,
Ka Ning Yip
AAPS-NERDG Chair 2024-2025
Senior Scientist I, Relay Therapeutics, Inc.
After the Morning Keynote, six students will present on their research to compete for the Academic Research Award (ARA). Concurrently, there will be three sessions of Short Topic Presentations (STP) with talks on a range of pharmaceutical research areas. We will once again have awards for the best STP presenters from each category. Winners from both sessions will be announced in the Awards Ceremony later in the day.
Before and after lunch, there are two exciting scientific presentations by DigiM and Simulations Plus, followed by one hour of Poster Session. All attendees will have an opportunity to interact with poster presenters and have great scientific discussions. Four Round Table Discussion sessions will follow, which include in-depth presentations by our panelists on emerging topics in pharmaceutical development. After our Second Keynote, our conference will conclude with an Awards Ceremony followed by a Networking Reception.
A vendor exhibition is available throughout the day, please take some time to visit their exhibition tables and listen to their technical talks. This conference would not be possible without our sponsors, supporters, and the incredible group of volunteers who have tirelessly worked to organize this year’s conference. Putting together an event of national recognition requires a lot of commitment, planning, and flexibility – it truly takes a village. This meeting wouldn’t be possible without their hard work and dedication to AAPS-NERDG.
Please enjoy the conference!
Sincerely,
Ka Ning Yip
AAPS-NERDG Chair 2024-2025
Senior Scientist I, Relay Therapeutics, Inc.
Program schedule
Time |
Program |
Location |
6:30 – 8:00 am |
Vendor Setup |
Foyer |
7:30 – 8:30 am |
Registration and Breakfast All Day Coffee provided by KORSCH America |
NERDG Registration Table and Foyer |
7:45 – 8:30 am |
Poster Setup |
Salon D |
8:30 – 8:45 am |
Introduction |
Salon E and F |
8:45 – 9:30 am |
Keynote Presentation 1 Chemical Threats Countermeasures: From Repurposing To Innovative Delivery Dr. Patrick Sinko Distinguished Professor of Pharmaceutics Ernest Mario School of Pharmacy, Rutgers University |
Salon E and F |
9:30 – 9:45 am |
Vendor Presentation 1 Simulations Plus |
Salon E and F |
9:45 – 10:00 am |
Morning Break Sponsored by Schrodinger |
Foyer |
10:00 am – noon |
Short Topic Presentations Session 1: Advanced Drug Delivery Systems Session 2: Nanomedicine and Nucleic Acid Based Therapeutics Session 3: Next Generation Cancer Therapeutics Academic Research Award Presentations |
Salon C Salon B Salon A Conference Room 6 |
12:00 – 12:45 pm |
Lunch |
Salon E and F |
12:45 – 1:00 pm |
Vendor Presentation 2 DigiM |
Salon E and F |
1:00 – 2:00 pm |
Vendor Exhibits and Poster Presentations |
Foyer and Salon D |
2:00 – 3:30 pm |
Round Table Presentations Artificial Intelligence Applications in Pharmaceuticals Advancements in Pharmaceutical Sciences Sustainability: The Path Forward Biologics/Long Acting Injectables |
Salon C Salon B Salon A Conference Room 6 |
3:30 – 3:45 pm |
Afternoon Break Sponsored by Schrodinger |
Foyer |
3:45 – 4:30 pm |
Keynote Presentation 2 Evolution of Drug Products and Drug Therapies in the Pharmaceutical Industry Dr. Sudhakar Garad Global Head of Chemical and Pharmaceutical Profiling Novartis BioMedical Research |
Salon E and F |
4:30 – 4:45 pm |
Awards and Meeting Close Poster Awards sponsored by Distek |
Salon E and F |
4:45 – 5:30 pm |
Cocktail Hour Sponsored by Corealis Pharma |
Foyer |
Event Photography
Photographs will be taken throughout the day. Please note that the photographs taken at this event may appear on materials such as our website and LinkedIn page. If you would prefer not to be photographed, please let the photographer know.
Map
Keynote speaker 1
Chemical Threats Countermeasures: From Repurposing To Innovative Delivery
Dr. Patrick Sinko
Distinguished Professor of Pharmaceuticals
Ernest Mario School of Pharmacy, Rutgers University
Dr. Patrick Sinko
Distinguished Professor of Pharmaceuticals
Ernest Mario School of Pharmacy, Rutgers University
Bio:
Dr. Patrick J. Sinko is a Pharmacist and a Pharmaceutical Scientist at Rutgers, The State University of New Jersey. He is a Distinguished Professor and the Parke-Davis Endowed Chair in Pharmaceutics and Drug Delivery at the Ernest Mario School of Pharmacy. Dr. Sinko served as Chair of the Department of Pharmaceutics in the School of Pharmacy (1998-2008) and Associate Vice President for Research (2007-2018) in the Office of Research and Economic Development for Rutgers University. Dr. Sinko was elected Fellow in the American Association for the Advancement of Science (2011), the American Association of Pharmaceutical Scientists (2003), and the Controlled Release Society (2017). In 2023, he was elected to the National Academy of Inventors. Dr. Sinko served as the President of AAPS (2022-2023). Previously, he was elected to the AAAS Council and the Board of Scientific Advisors of the Controlled Release Society. Dr. Sinko has served on numerous scientific advisory and review panels in the United States and Europe. He is the Editor of Martin’s Physical Pharmacy and Pharmaceutical Sciences (Fifth through Eighth Editions) and is on the Editorial Advisory Board for numerous journals. He is the Editor-in-Chief for Pharmaceutics. Dr. Sinko has authored or co-authored over 540 publications, including research papers, abstracts, and book chapters (h-index = 67). He is the Principal Investigator of an active research laboratory focusing on biopharmaceutics, pharmaceutical formulations, and molecular-, nano-, and micro-scale drug delivery. The NIH has continuously funded his lab for over 30 years. During his career, Dr. Sinko has received several awards for his teaching and research, including the Rutgers University Board of Trustees Award for Excellence in Research and the highly selective National Institutes of Health FIRST and MERIT Awards.
Vendor presentation 1
|
Dan O’Connor
Senior Director, Business Development Simulations Plus, Inc. |
|
AI ... All Aboard!
Abstract:
The presentation will explore the transformative role of AI (artificial intelligence) in drug discovery and development, focusing specifically on its application in Simulations Plus’ GastroPlus and ADMET Predictor modeling and simulation platforms, and the impact on pharmaceutical research.
Bio:
Since joining Simulations Plus in 2017, Dan is dedicated to representing the needs of our clients to our team of scientists so that we may provide expert modeling and simulation software, solutions, and services… on time, on spec, and on budget.
Dan is a business development expert with 30 years of experience in alliance management and business development for the pharma/biotech industry. Skilled in B2B sales, networking, and growing relationships with customers and prospects. Strong international relations with North America, LATAM, EU, APAC and MEA markets.
“Happy to assist you in any way, please just let me know!”
Abstract:
The presentation will explore the transformative role of AI (artificial intelligence) in drug discovery and development, focusing specifically on its application in Simulations Plus’ GastroPlus and ADMET Predictor modeling and simulation platforms, and the impact on pharmaceutical research.
Bio:
Since joining Simulations Plus in 2017, Dan is dedicated to representing the needs of our clients to our team of scientists so that we may provide expert modeling and simulation software, solutions, and services… on time, on spec, and on budget.
Dan is a business development expert with 30 years of experience in alliance management and business development for the pharma/biotech industry. Skilled in B2B sales, networking, and growing relationships with customers and prospects. Strong international relations with North America, LATAM, EU, APAC and MEA markets.
“Happy to assist you in any way, please just let me know!”
Academic Research Award (ARA)
Conference Room 6
Conference Room 6
Moderator: Dimple Modi
Time |
Title |
Presenting Author |
Affiliation |
10:00 - 10:20 am |
PNA-mediated targeting of the oncogenic miRNA 17-92 cluster |
Ivy Browne |
University of Saint Joseph |
10:20 - 10:40 am |
Chemically engineered nucleic acids targeting VEGFA genomic DNA for cancer therapy |
Angana De |
University of Connecticut |
10:40 - 11:00 am |
CFD-DEM modelling of Suspension Mixing in Pharmaceutical Manufacturing |
Saeed Najafian |
University of Connecticut |
11:00 - 11:20 am |
Preparation and characterization of an ultraflexible liposomal gel for transdermal delivery of a novel pan-RAS inhibitor for the treatment of melanoma cancer |
Shivani A. Dave |
Massachusetts College of Pharmacy |
11:20 - 11:40 am |
A Novel Excipient-Based Solid Oral Dosage Form: Formulation, Characterization and Prediction of Clinical Outcomes |
Zia Uddin Masum |
St. John's University |
11:40 am - 12:00 pm |
Prediction of surfactant-mediated dissolution of poorly soluble drugs from drug powder |
Roshni Patel |
University of Maryland Baltimore |
Short Topic Presentations (STP) Session 1: Advanced Drug Delivery Systems
Salon C
Salon C
Moderator: Suraj Fanse
Time |
Title |
Presenting Author |
Affiliation |
10:00 - 10:30 am |
Impact of Drug Incorporation into Micelle on Reduced Griseofulvin Across a Hollow Fiber Membrane |
Roshni Patel |
University of Maryland Baltimore |
10:30 - 11:00 am |
Understanding in situ Forming implants with Modified API Attributes |
Mckenzie Roy |
University of Connecticut |
11:00 - 11:30 am |
Revolutionizing Women's Health by Enabling the Rational Development of Long-Acting Contraceptive Levonorgestrel Intrauterine Systems |
Ashwin Abhang |
University of Connecticut |
11:30 am - 12:00 pm |
Investigating the Small and Macromolecular Composition of Pseudoalteromonas piscicida JC3 Membrane Vesicles |
Ololade Gbadebo |
University of Rhode Island |
Short Topic Presentations (STP) Session 2: Nanomedicine and nucleic acid based therapeutics
Salon B
Salon B
Moderator: Veeran Kadajji
Time |
Title |
Presenting Author |
Affiliation |
10:00 - 10:30 am |
Optimization of Novel Ionizable Lipid Nanoparticles for Enhanced siRNA Delivery |
Mittal Darji |
University of Connecticut |
10:30 - 11:00 am |
Using Coarse-Grain Molecular Dynamics to Investigate DNA-Surfactant Conjugates as a Platform for Therapeutic Nucleic Acid Delivery |
Patrick Corrigan |
University of Connecticut |
11:00 - 11:30 am |
Enhancing the Stability of eGFP mRNA-LNPs: THe Role of Lyoprotectant Combinations in Post-Lyophilization Preservation |
Zixuan Zhen |
University of Connecticut |
11:30 am - 12:00 pm |
Evaluating Nucleic Acid Nanocapsules (NANs) as Nucleic Acid Delivery Vehicles: From Cellular to Animal Models |
Jenna Cannata |
University of Connecticut |
Short Topic Presentations (STP) Session 3: Next Generation Cancer Therapeutics
Salon A
Salon A
Moderator: Vivek Gupta
Time |
Title |
Presenting Author |
Affiliation |
10:00 - 10:30 am |
Next-Generation Antisense Strategy to Target AKT Genes for Breast Cancer Therapy |
Natasha Shah |
University of Saint Joseph |
10:30 - 11:00 am |
Targeting the Genomic DNA of the Undruggable c-Myc Oncogene for Cancer Therapy |
Ruchi Ruchi |
University of Connecticut |
11:00 - 11:30 am |
Carnitine-Tailored SNEDDS for Targeted Delivery of A1874 PROTAC in Glioblastoma via OCTN2 Receptor |
Himaxi Patel |
St. John's University |
11:30 am - 12:00 pm |
Exploring the Efficacy of Inhaled Antimalarial Drug Against Non-Small Cell Lung Cancer |
Meghana Mokashi |
St. John's University |
Vendor presentation 2
|
Andrew G. Clark
Director of Pharmaceutical Sciences DigiM solution |
|
In Situ Imaging of Drug Release as a Mechanistic Formulation Guide
Abstract:
There is great interest in understanding the exact mechanisms of disintegration and dissolution of pharmaceutical dosage forms and in particular how the functional excipients behave to drive dissolution. However given the range of timescales and the three-dimensional nature of the dissolution process, a mechanistic description of dissolution has proven to be extremely challenging to validate and verify. In this work we present dissolution and functional excipient characterization through development and implementation of time resolved 3D imaging of controlled release oral formulations. Extended release (ER) and immediate release (IR) tablets were used to develop time resolved imaging methods. Micro computed tomography (µCT) was performed using a lab-scale instrument, as well as at a synchrotron light source for improved time resolution. Structural changes including tablet swelling, fracture/pore development, and changes in excipient size distribution were quantified and correlated to the different exposure methods. The development of in situ imaging offers the potential to improve dissolution performance by elucidating dissolution mechanisms and correlating to both formulation and processing parameters.
Bio:
Andrew Clark serves as the Director of Pharmaceutical Science at digiM Solution, where he leads the research and application of advanced characterizations to aid in the development of drug products across the development pipeline. He has pioneered the routine usage of synchrotron-based CT methods as well as advanced CT density characterization in the study of drug product formulations. He earned his PhD in experimental physics at Tufts University characterizing advanced polymeric materials, and has leveraged this skills in his roles at digiM Solution.
Abstract:
There is great interest in understanding the exact mechanisms of disintegration and dissolution of pharmaceutical dosage forms and in particular how the functional excipients behave to drive dissolution. However given the range of timescales and the three-dimensional nature of the dissolution process, a mechanistic description of dissolution has proven to be extremely challenging to validate and verify. In this work we present dissolution and functional excipient characterization through development and implementation of time resolved 3D imaging of controlled release oral formulations. Extended release (ER) and immediate release (IR) tablets were used to develop time resolved imaging methods. Micro computed tomography (µCT) was performed using a lab-scale instrument, as well as at a synchrotron light source for improved time resolution. Structural changes including tablet swelling, fracture/pore development, and changes in excipient size distribution were quantified and correlated to the different exposure methods. The development of in situ imaging offers the potential to improve dissolution performance by elucidating dissolution mechanisms and correlating to both formulation and processing parameters.
Bio:
Andrew Clark serves as the Director of Pharmaceutical Science at digiM Solution, where he leads the research and application of advanced characterizations to aid in the development of drug products across the development pipeline. He has pioneered the routine usage of synchrotron-based CT methods as well as advanced CT density characterization in the study of drug product formulations. He earned his PhD in experimental physics at Tufts University characterizing advanced polymeric materials, and has leveraged this skills in his roles at digiM Solution.
Vendor Exhibits
Foyer
Foyer
Asahi Kasei |
JRS Pharma |
|
Austin Px |
Sever |
|
BASF |
The Solubility Company |
|
FreeThink |
poster presentation Session
Salon D
Salon D
Poster Number |
Poster Title |
Presenting Author |
Presenting Author Affiliation |
1 |
Time-Dependent Relative Humidity in Nested Packaging |
Vanessa M Breslin |
FreeThink Technologies, Inc. |
2 |
Targeted Delivery of siRNA to the Kidneys Using Mesoscale Lipid Nanoparticles |
Anastasiia Vasylaki |
City College of New York |
3 |
PKPD Modeling and Quantitative Analysis of Immunotherapy Drug Pembrolizumab |
Reyana Celebi |
Albany College of Pharmacy and Health Sciences |
4 |
Albumin is a critical factor contributing to plasma per- and polyfluoroalkyl substances (PFAS) concentration, accumulation, and retention in vivo |
Olga Skende |
University of Rhode Island |
5 |
Optimizing Process Analytical Technology: Refractometer in Continuous Manufacturing of Lipid-Based Therapeutics |
Luke Burroughs |
University of Connecticut |
6 |
Evaluation of Cluster of differentiation 36 (CD36) as a critical factor in perfluorooctanesulfonic acid (PFOS)-induced adverse liver outcomes |
Jingmei Zeng |
University of Rhode Island |
7 |
Investigating the Cellular Internalization and Endosomal Escape of Polymeric Mesoscale Nanoparticles |
Poojaa Jayanthi Venugopal |
City College of New York |
8 |
In Vitro Lipolysis Model to Predict Food Effect of Poorly Water-Soluble Drugs Itraconazole, Rivaroxaban, and Ritonavir |
Roshni Patel |
University of Maryland Baltimore |
9 |
Accelerated Stability Assessment Program (ASAP) Study of Peroxides in Excipients |
Jesse D. Scalesi and Louis Somma |
FreeThink Technologies, Inc. |
10 |
Innovative Thermosensitive Hydrogel for Probiotic Delivery in Reproductive Tract Diseases: Enhancing Stability and Antibacterial Efficacy |
Jiantao Zhang |
Chinese Academy of Sciences |
11 |
Influence of Terminal Groups on PLGA Degradation and Their Role in the Sustained Release of Cyproterone Acetate |
Jiantao Zhang |
Chinese Academy of Sciences |
12 |
Non-gelatin Film Coatings for Formulating Easy-to-Swallow Tablets |
Kun Chen |
BASF Corporation |
13 |
Validating metabolic relevance of Nw-hydroxy L-Arginine to inflammatory and immune-checkpoint molecules based on breast cancer estrogen-receptor status |
Srinidi Mohan |
University of New England |
14 |
Exploring the Potential of Polyvinyl Acetate and PVP-90 to Prevent Alcohol Dose Dumping (ADD) and Considerations for Regulatory Guidance(s) |
Ming Ji |
BASF Corporation |
15 |
ZoomLab-Enabled Design & Development of Rapidly Disintegrating Loratadine Tablets |
Sravani Reddy |
St. John's University |
16 |
Repurposing the Unchained Labs Hound particle characterization instrument to maximize understanding of solid form during small molecule preclinical development |
Robert Ozburn |
Pfizer Inc. |
17 |
Dissolution Method Design Based Upon Molecule PhysChem Properties and Human Gastroinstestinal Physiology |
Joseph Middleton |
Pfizer Inc. |
18 |
Quantifying the Intrinsic Effects of Lubrication to Predict the Tensile Strength of Pharmaceutical Formulations |
Allan Hutchins |
Pfizer Inc. |
19 |
Predictions of Drug Release in Bilayer Osmotic Tablets |
Bhawana Singh Tomar |
Pfizer Inc. |
20 |
Roller Compacted Ribbon Solid Fraction Measurement Methods Design Space |
Amanda Strenk |
Pfizer Inc. |
21 |
Improved microemulsion formation of clofazimine lipid digestion product-based SEDDS using linoleic acid. |
Hari P Kandagatla |
St. John's University |
22 |
Impact of excipient purity on in vitro efficacy and safety of siRNA-loaded lipid nanoparticles |
Sheyda Ranjbar |
University of Connecticut |
23 |
Nanoparticle-Mediated Inhalation Delivery of Celastrol for Targeted Therapy in non-small cell lung cancer (NSCLC) |
Mural Quadros |
St. John's University |
24 |
A Nano-emulsion Formulation for Improved Oral Bioavailability of Sorafenib, and Potential Repurposing for Lung Cancer Treatment |
Sanjana Durve |
St. John's University |
25 |
Inhalable Liposomal Clofazimine for Targeted Pleural Mesothelioma treatment |
Suman Choudhary |
St. John's University |
26 |
Impact of Particle Size Reduction Technique on the Performance of Long-Acting Injectable Suspensions |
Saurabh Bhorkade |
University of Connecticut |
Round table session 1: Artificial Intelligence Applications in Pharmaceuticals
Salon c
Salon c
Moderators: Lina Niu and Sandip Tiwari
Presentation Title |
Invited Presenter |
Affiliation |
Operation Oppenheimer: how we get in and out of the Machine Learning (ML) modeling rabbit hole for LC retention prediction |
Jane Kawakami |
Pfizer Inc. |
Management of AI technologies |
Jordan W. Suchow |
Stevens Institute of Technology |
A highly accurate, reliable, and efficient CSP platform and FEP+ solubility prediction workflow for small molecule drug formulation |
Shiva Shekharan |
Schrodinger |
round table session 2: advancements in pharmaceutical Sciences
salon b
salon b
Moderators: Heather Frericks Schmidt and Jayshil Bhatt
Presentation Title |
Invited Presenter |
Affiliation |
Particle Engineering of Amorphous Solid Dispersions by Atomic Layer Coating |
Dana Moseson |
Pfizer Inc. |
Application of an Interdisciplinary Approach to Form Selection |
Darren Reid |
Amgen Inc. |
Polymeric Mesoscale Nanoparticles Selectively Target Gene Therapies to the Kidneys |
Ryan Williams |
The City University of New York |
round table session 3: sustainability: The Path Forward
salon a
salon a
Moderators: Jennifer Chu and Raxit Mehta
Presentation Title |
Invited Presenter |
Affiliation |
Carbon Footprints – The Next Step on the Path Forward |
Michael Royko |
BASF Pharma Solutions |
Sustainability in Pharma - Croda ingredients and initiatives |
Sreejit Menon |
Croda Pharma |
Transition to Sustainable Blister Packaging in the Pharmaceutical Industry |
Eben Frenzel |
Pfizer Inc. |
round table session 4: biologics/Long Acting injectables
Conference room 6
Conference room 6
Moderators: Dimple Modi and Veeran Kadajji
Presentation Title |
Invited Presenter |
Affiliation |
Drug Product Design and Manufacturability Considerations for Long Acting Suspension Products |
Chandan Bhugra |
GSK |
Route Agnostic Vehicles for Non-invasive Delivery of Large Molecule Therapeutics |
Vivek Gupta |
St. John's University |
AI-driven automation for LAI discovery and scale-up – A Case Study |
Karthik Raman |
Persist AI |
Keynote speaker 2
Evolution of Drug Products and Drug Therapies in the Pharmaceutical Industry
Dr. Sudhakar Garad
Global Head of Chemical and Pharmaceutical Profiling
Novartis BioMedical Research
Dr. Sudhakar Garad
Global Head of Chemical and Pharmaceutical Profiling
Novartis BioMedical Research
Bio:
Sudhakar Garad received his Ph.D. from the University of Mumbai, India in 1998 in Pharmaceutical Drug Delivery Technology. Soon after completion of his Ph.D., he worked with Pfizer, India for less than a year in clinical research. Taking into consideration his excellent credentials during his Ph.D., he was selected as a post-doctoral fellow at the University of Connecticut to understand micro-environmental properties above dissolving surface of the polymers with Dr. Robin Bogner. After his post-doctoral fellowship, he worked with Vertex pharmaceutical for a period of three years as Senior Investigator in formulation development group. After Vertex, he joined Novartis as a Group Head in Developability Assessment team. He worked with Novartis for 9 years and joined as a Director of formulation development at Cubist Pharmaceuticals/Merck for 2.5 years. Currently Sudhakar is working as a Global head of Chemical and Pharmaceutical profiling (Pre-formulation/Novel Drug Delivery) and Technical R and D, Biopharmaceutics Head at Novartis. His primary role is collaborating with research colleagues and build the right biopharmaceutical properties into new chemical entities, if not enable them via solubility/dissolution enhancement technologies for poorly soluble molecules to expedite molecules into tox and clinical studies. He is also responsible for enabling research, clinical and commercial molecules via novel delivery technologies (Brain targeting, permeability enhancement, TI improvement etc). As Biopharmaceutics head he looks after entire portfolio with physical form, formulation process changes which impacts BA/BE. He has many publications, book chapters and patents. In last 23 years of his career, he has selected more than 300 new chemical entities in clinical studies across dozen disease areas (CVM, Oncology, ATI, MS, Respiratory, NS, GI, Antibacterial, Tropical diseases, HCV etc), via oral, parenteral, inhalation and transdermal route of administration.
NERDG Planning Committeee VOlunteers
* Indicates Committee Leads
Chair |
Vice-Chair |
Past Chair |
Treasurer |
Ka Ning Yip Relay Therapeutics |
Snehal Shukla Pfizer |
Anand Gupta GSK |
Dana Gates |
|
|
27th Annual AAPS-NERDG Conference Sponsors
Gold Corporate Sponsors
Merck
GSK
Pfizer
Sotax
Simulations Plus
DigiM Solution
Other Corporate Sponsors
/Exhibitors
AustinPx
Free Think Tech
Distek Inc.
JRS Pharma
Sever Pharma Solutions
BASF
Asahi Kasei
The Solubility Company
Korsch
Corealis Pharma
Boehringer Ingelheim
Schrödinger
Barentz
